Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Revolution Medicines, boosting the price target to $104.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Charles Zhu has given his Buy rating due to a combination of factors that highlight Revolution Medicines’ promising future prospects. The company has initiated the RASolute 304 trial, which is significant as it targets resectable pancreatic ductal adenocarcinoma (PDAC) with a focus on disease-free survival as the primary endpoint. This trial, along with the ongoing RASolute 302 trial, underscores the company’s commitment to advancing its pipeline and achieving key milestones.
Furthermore, Revolution Medicines has demonstrated strong financial health, with $1.93 billion in cash and equivalents as of September 30, 2025, and additional potential capital from royalty agreements. The management’s confidence in their commercial readiness and strategic scaling efforts to support future launches further solidify the company’s position. These elements combined suggest a robust growth trajectory, justifying the Buy rating.
In another report released on November 3, RBC Capital also initiated coverage with a Buy rating on the stock with a $77.00 price target.